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Stromal fibroblasts are the primary cells of the kidney that
produce fibrotic matrix. CD248 is a stromal marker expressed
on fibroblasts and pericytes within the human kidney. Here,
we tested whether CD248 expression in the kidney
colocalizes with fibrosis and if it is associated with known
determinants of chronic kidney disease (CKD). CD248
expression was located and quantified in situ by
immunohistochemistry in kidney biopsies from 93 patients
with IgA nephropathy and compared with 22 archived
biopsies encompassing normal kidney tissue as control. In
normal kidney tissue, CD248 was expressed by resident
pericytes, stromal fibroblasts, and was upregulated in human
CKD. The expression was linked to known determinants of
renal progression. This relationship was maintained in a
multivariate analysis with CD248 expression linked to renal
survival. CD248 was expressed by a population of a-smooth
muscle actin (SMA)þ myofibroblasts and a-SMA stromal
cells but not expressed on CD45þ leukocytes. Thus, CD248
defines a subset of stromal cells, including but not limited to
some myofibroblasts, linked to albuminuria and
tubulointerstitial damage during tissue remodeling in CKD.
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Stromal fibroblasts are the primary fibrotic matrix-producing
cells of the kidney. To date, there have been few systematic
studies of stromal fibroblasts in human chronic kidney
disease (CKD), reflecting the lack of cell-specific fibroblast
markers.1
The most commonly used marker of an activated renal
fibroblast, known as a myofibroblast, has been a-smooth
muscle actin (a-SMA).2 However, a-SMA may actually
suppress and control myofibroblast activity,3 and therefore
does not represent a viable therapeutic target. Pioneering
work by Strutz et al.4–7 demonstrated that tubular epithelial
cells can express fibroblast markers in various disease states,
suggesting that epithelial–mesenchymal transformation is a
potent source of myofibroblasts. Proximal tubular epithelial
cells acquiring a fibroblast phenotype were accompanied by
the de novo expression of fibroblast specific protein-1
(FSP-1)8 indicating that FSP-1 may be a marker of
epithelial–mesenchymal transformation. In an ex vivo study
in human IgA nephropathy with preserved kidney function,
there was a negative correlation between FSP-1 and renal
survival.9 However, these observations are confounded by
FSP-1 expression on infiltrating leukocytes that by themselves
are known determinants of progressive CKD.10–12
CD248 is a stromal cell marker13 that may represent a
more precise marker of fibrosis and a viable target for
therapy. This type I transmembrane glycoprotein was
originally identified using an antibody panel raised against
fetal fibroblasts.13 At nonrenal sites, CD248 definitively
localizes to fibroblasts and pericytes found in inflammatory
and cancer stroma, suggesting a pivotal role in tissue
remodeling and repair.14
At basal levels in the adult kidney, CD248 is expressed in
the glomerulus on specialized pericytes more commonly
referred to as mesangial cells.15 In renal cell carcinoma, the
expression is significantly increased and large rafts of CD248-
positive fibroblasts can be seen within the interstitium.15
Similar patterns of CD248 expression are seen within other
organs during malignant disease.16
In vitro studies have shown that fibronectin, collagen type
I, and collagen type IV act as specific ligands for CD248 with
adhesion and migration mediated through CD248.17 CD248
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regulates cell proliferation in vivo,18 and this process is
mediated through platelet-derived growth factor receptor
signaling.19 Murine models have demonstrated that CD248 is
anatomically and temporally regulated with high levels of
expression found in the embryo and newborn tissue,20 and
low levels in normal adult tissues. CD248 knockout mice
develop normally, and have normal postnatal growth and
wound healing.21 However, if tumors are implanted in the
abdominal cavity, there is impaired tumor growth, invasion,
and metastasis. This indicates that CD248 may have a critical
role in determining tumor behavior. Recently, Maia et al.22
have demonstrated using a murine model of arthritis that
CD248 contributes to synovial hyperplasia, fibrosis, and
leukocyte accumulation in inflammatory arthritis and that
CD248 may represent a target for the treatment of arthritis.
Indeed, a monoclonal anti-human CD248 antibody (MOR-
Ab-004) is currently undergoing phase 1 clinical trials for the
treatment of solid tumors (ClinicalTrials.gov identifier:
NCT008470544).
We therefore hypothesized that CD248 expression is
upregulated in CKD and may be a potential therapeutic target.
Initially, we reaffirmed earlier observations from the studies of
other groups13,14 concerning the expression of CD248 in normal
renal tissue before characterizing CD248 expression in patients
with progressive CKD. We related CD248 expression to known
in situ determinants of renal progression to assess the relevance
of this molecule in human kidney disease.
RESULTS
Characterization of CD248 expression in cultured human
renal cells
We isolated renal fibroblasts from the nonaffected pole of
human kidney samples removed for the treatment of malig-
nant disease to examine CD248 expression in vitro. CD248
was expressed by renal fibroblasts (n¼ 3) but not by glomer-
ular endothelial cells, podocytes, or human umbilical vein
endothelial cells. Protein and RNA expression was confirmed
by western blotting and reverse transcription-PCR, respec-
tively (Figure 1). Explant culture may potentially lead to
fibroblast activation, and thus expression of CD248 in vivo
expression was also investigated.
Characterization of CD248 expression within normal kidney
To examine CD248 expression in human renal stromal cells
in vivo, we performed immunohistochemistry on a control
group of patients with archived tissue taken from the
nonaffected pole of nephrectomies performed for the
treatment of malignant disease (n¼ 22, 9 females and 11
males; median age 65, range 39–85). All control patients had
normal renal function (estimated glomerular filtration rate
(eGFR)490). These studies demonstrated CD248 expression
within the glomerulus, localized to mesangial cells (Figure 2).
Tubulointerstitial staining was scant, and when found present
it was localized to the interstitial space.
To further identify renal cell populations expressing
CD248 in normal kidney, we also examined kidney tissue
taken from healthy adult mice (Figure 3). CD248 shares
similar homology in humans to mice. Murine tissue
permitted more detailed confocal microscopy studies to be
performed on noninflamed tissue. Again, CD248 localized to
mesangial cells of the glomerulus, but it was also seen in
pericytes wrapped around peritubular blood vessels (Figure 3)
and on interstitial peritubular fibroblasts.
In summary, in healthy noninflamed kidney, CD248 is
expressed by resident pericytes and on stromal fibroblasts.
Characterization of CD248 expression in relationship to
known determinants of renal progression
To investigate the potential role that CD248 may play in
tissue remodeling that accompanies progressive CKD, we
performed a detailed histological analysis of a cohort of
patients with IgA nephropathy. IgA nephropathy was chosen
as progression in these patients is known to be tightly linked
to albuminuria and interstitial fibrosis at diagnosis.23
A total of 100 patients with an adequate renal biopsy to
make a diagnosis of IgA nephropathy were identified. Of
these, 93 had archived tissue and clinical data suitable for
analysis (60 males and 33 females). Table 1 summarizes the
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Figure 1 |CD248 expression in vitro. (Top) Confocal microscopy
studies demonstrated CD248 expression by renal fibroblasts (RFs)
(n¼ 3), but not by human umbilical vein endothelial cells
(HUVECs), glomerular endothelial cells (GECs), or podocytes
(POD) (data not shown). (Middle and bottom) Reverse
transcription-PCR (RT-PCR) and western blotting corroborated the
immunostaining pattern observed.
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clinical, pathological, and experimental characteristics ana-
lyzed. Histological analysis of the biopsy samples demons-
trated diffuse tubulointerstitial staining for CD248 (Figure 2).
CD248 expression was also seen to be increased in the
mesangial cells of the glomerulus in inflamed kidney tissue
(Figure 2f). Quantification of the interstitial staining using an
interactive image analysis system showed expression to be
greater in patients with more advanced disease. Previous
studies by our group12,24 have demonstrated the relationship
between albuminuria, renal function, index of chronic
damage, and progressive CKD. We therefore analyzed the
relationship between these parameters and CD248 expression
in situ in our IgA cohort.
By univariate analysis, urinary albumin–creatinine ratio
(ACR) correlated with tubulointerstitial expression of CD248
(correlation 0.500; Po0.0000; Table 2 and Figure 4). eGFR
inversely correlated with urinary ACR but not as strongly
as tubulointerstitial CD248 expression (correlation 0.360;
P¼ 0.0004; Table 2 and Figure 4). Interstitial CD248 expres-
sion correlated with renal fibrosis as assessed by the index of
chronic damage (correlation 0.539; Po0.0000) and eGFR
(correlation 0.679; Po0.0000; Table 2 and Figure 4).
Importantly, these univariate correlations were main-
tained in a multivariate linear regression analysis of the
variables. Tubulointerstitial CD248 expression, urinary ACR,
index of chronic damage, and eGFR were all interdependent
variables (Table 3). Notably, tubulointerstitial CD248 expres-
sion independently associated with urinary ACR (0.299;
P¼ 0.002). Again, as we have previously published12,24 using
other disease cohorts, classical determinants of CKD
progression, for example, urinary ACR and eGFR, were
interdependent.
Does CD248 colocalize with a-SMA in advanced CKD?
Depletion of a-SMA has previously proven detrimental to the
progression of renal disease.3 We therefore wished to identify
if CD248 was expressed by a-SMAþ myofibroblasts to help
determine if CD248 may represent a viable target for the
treatment of CKD. Confocal microscopy was used to localize
a-SMA and CD248 in advanced IgA nephropathy (n¼ 3).
Again, CD248 was found to be localized to the tubulointer-
stitium. Immunofluorescence demonstrated three subsets of
CD248þ stromal cells: CD248þaSMA, CD248þaSMAþ ,
and CD248aSMAþ (Figure 5). CD248 did not colocalize
with the leukocyte marker CD45 (Figure 2).
Renal survival
To assess if CD248 expression is an independent predictor of
renal survival, we reviewed the renal outcomes of our cohort.
Data on renal outcome were available for all 93 patients studied.
Patients were followed for up to 1095 days following renal
biopsy. A total of 19 patients reached a renal end point
(7 patients doubled their serum creatinine, and 12 patients
reached end-stage renal failure) after a mean period of 285 days
(range 1–975 days; one patient commenced dialysis at day 1).
Kaplan–Meier survival analysis demonstrates that patients
with extensive tubulointerstitial staining for CD248, parti-
cularly tubulointerstitial CD248 49.8%, is predictive of
poorer renal outcome (log rank testing for equality of
survivor function statistic w2¼ 18.28, P¼ 0.0001). Similar
predictive outcomes were seen for albuminuria (w2¼ 25.72,
P¼ 0.0001) and index of chronic damage (w2¼ 31.74,
P¼ 0.0001; Figure 4). Therefore, univariate and multivariate
analyses of these variables were performed. This demon-
strated CD248 to be an independent predictor of renal
survival in our cohort (Table 4).
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Figure 2 | Immunohistochemistry for CD248. Normal human
kidney (n¼ 22). (a) CD248 (brown) localizes to the vascular pole
(arrow) with weak expression seen in the mesangial cells of the
glomerulus (original magnification  100). There is scant
expression in the tubulointerstitium on peritubular fibroblasts (*).
(b) Glomerular expression of CD248 (original magnification
 400). (c) In progressive chronic kidney disease (CKD; n¼ 93)
there is diffuse expression of CD248 throughout the
tubulointerstitium. Shown at higher power in d and e (arrow to
CD248 staining). (f) Glomerular expression of CD248 was also
increased in the mesangial cells of inflamed kidney (original
magnification  630). (g) Confocal microscopy to colocalize
CD248 (green) and a-smooth muscle actin (a-SMA; red) (original
magnification  100). Distinct sub-populations (**) can be seen
and are described in more detail in Figure 5. (h) CD248 (green)
was not expressed by CD45-positive cells (red; arrow).
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DISCUSSION
This study characterizes the expression of the stromal cell
marker CD248 in normal kidney and in the kidney tissue of a
cohort of patients with progressive renal disease. IgA
nephropathy was chosen as a model of progressive human
CKD because classical determinants of renal progression are
recognized to be important in determining long-term renal
survival in these patients.9,12 CD248 has previously been
demonstrated to be expressed on fibroblasts and pericytes
found within inflammatory stroma.15
The in-house anti-CD248 antibodies used in this study
have been extensively characterized within the literature, both
in vitro13,25 and in vivo,14,26 to recognize fibroblasts and
pericytes, and the studies presented here are further confir-
mation of this specificity. Importantly, they do not recognize
endothelial cells or leukocytes.26 Although in humans a
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Figure 3 | In normal, noninflamed kidney, CD248 is expressed by resident renal pericytes. Murine tissue was analyzed. Glomerular
expression of CD248. CD248 (c) localizes to mesangial cells of the glomerulus identified by platelet-derived growth factor receptor-b
(PDGFRb; panel a green and arrow panel d cyan) but does not colocalize with CD31-positive endothelial cells (red; b, f). CD248 (g; blue)
does not colocalize with podocytes identified with synaptopodin (e; green). (d, h) Composite images. (i–k) Tubulointerstitial expression of
CD248. CD248 is expressed by pericytes wrapped around peritubular blood vessels. E-cadherin (green) identifies tubular epithelial cells.
CD31 (red; arrow, panel n)-positive endothelial cells within the interstitium are supported by CD248-positive pericytes (blue; arrow, panel m).
Merged image shown in l and zoomed images in m–o.
Table 1 | Study population: clinical, pathological, and
experimental characteristics (n=93)
Median Range
Age (years) 42 18–82
eGFR (ml/min per 1.73m2) 56 6–99
ACR (mg/mmol) 60 0.8–1097
Index of chronic damage (%) 17 0–94
Tubulointerstitial CD248 (%) 6.8 1.42–31.57
Abbreviations: ACR, albumin–creatinine ratio; eGFR, estimated glomerular
filtration rate.
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population of CD8þCD45þ T cells and also a population of
vascular leukocytes have been reported,27,28 importantly no
CD248þCD45þ cells were seen in our study.
Our in vitro and in vivo studies have shown in healthy
noninflamed kidney that CD248 is expressed by resident
pericytes and on stromal fibroblasts. In injured fibrotic
kidney tissue, CD248 is increased and expressed on a sub-
population of myofibroblasts (CD248þaSMAþ ) in addition
to a population of CD248þaSMA stromal fibroblasts.
CD248aSMAþ myofibroblasts were also seen. We were
unable to phenotype these cells further using the tissue
samples that we had available; however, this is the first
description of a novel myofibroblast population that is
CD248þaSMAþ and also of CD248þaSMA fibroblasts.
The origin and heterogeneity of renal stromal
myofibroblasts is diverse and recruitment may occur either
Table 2 | Univariate analysis of correlations between urinary ACR, tubulointerstitial CD248, index of chronic damage, and
serum creatinine (n=93)
Urinary ACR Tubulointerstitial CD248 Index of chronic damage
Correlation; P-value Correlation; P-value Correlation; P-value
Urinary ACR NA
Tubulointerstitial CD248 0.500; 0.0000* NA
Index of chronic damage 0.512; 0.0000* 0.539; 0.0000* NA
eGFR 0.360; 0.0004* 0.515; 0.0000* 0.679; 0.0000*
Abbreviations: ACR, albumin–creatinine ratio; eGFR, estimated glomerular filtration rate; NA, not applicable.
*Po0.05.
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Figure 4 |Plots of correlation (correlation; P-value). Plots of correlation between (a) albumin–creatinine ratio (ACR) and tubulointerstitial
CD248 staining (0.500; Po0.0000), (b) index of chronic damage and tubulointerstitial CD248 (0.539; Po0.0000), and (c) estimated
glomerular filtration rate (eGFR) and tubulointerstitial CD248 (0.679; Po0.0000). Kaplan–Meier analysis of (d) urinary ACR on renal
outcome (w2¼ 25.72, P¼ 0.0001); (e) index of chronic damage (ICD) on renal outcome (w2¼ 31.74, P¼ 0.0001), and (f) tubulointerstitial
expression of CD248 on renal outcome (w2¼ 18.28, P¼ 0.0001).
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Table 3 |Multivariate linear regression analysis between urinary ACR, tubulointerstitial CD248, index of chronic damage, and
serum creatinine (n=93)
Dependent variable
Urinary ACR Tubulointerstitial CD248 Index of chronic damage eGFR
b; P-value b; P-value b; P-value b; P-value
Urinary ACR NA 0.299; 0.002* 0.253; 0.003* 0.517; 0.577
Tubulointerstitial CD248 0.329; 0.002* NA 0.150; 0.097 0.225; 0.019*
Index of chronic damage 0.380; 0.003* 0.204; 0.097 NA 0.584; 0.000*
eGFR 0.067; 0.577 0.268; 0.019* 0.510; 0.000* NA
Abbreviations: ACR, albumin–creatinine ratio; eGFR, estimated glomerular filtration rate; NA, not applicable.
*Po0.05.
Nuclei CD248 Mergeα-SMA
Figure 5 |Confocal microscopy. Human renal biopsy samples from patients with chronic kidney disease (CKD) 3 and 4 (n¼ 3) were stained
to colocalize a-smooth muscle actin (a-SMA; red) and CD248 (green). Nuclei are shown in blue. CD248þaSMA, CD248þaSMAþ , and
CD248aSMAþ sub-populations can be seen in all biopsy samples and specific cell populations are highlighted in each panel.
(a) CD248þaSMA (arrows). (b) CD248aSMAþ (arrow). (c) CD248þaSMAþ (arrows).
Table 4 | Univariate and multivariate analyses of the impact of studied variables on renal survival
Urinary ACR Exp(B);
P-value; 95% CI
Tubulointerstitial CD248
Exp(B); P-value; 95% CI
Index of chronic damage
Exp(B); P-value; 95% CI
Age Exp(B);
P-value; 95% CI
Sex Exp(B);
P-value; 95% CI
eGFR Exp(B);
P-value; 95% CI
Univariate 2.120; o0.0001 44.997; o0.0001 1.666; o0.0001 1.008; 0.561 1.113; 0.821 0.935; o0.0001
1.428–3.146 7.649–264.712 1.324–2.096 0.982–1.034 0.438–2.82 0.908–0.963
Multivariate NS 12.09; 0.008; NS 0.968; 0.008 NS 0.934; o0.0001
1.89–77.39 0.942–0.995 0.905–0.964
Abbreviations: ACR, albumin–creatinine ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; NS, not statistically significant.
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from the resident cell populations, from circulating bone
marrow-derived precursors, or through the process of
epithelial–mesenchymal transformation.8 Iwano et al.29 have
attempted to describe, in animal models, the relative
importance of the various potential sources of fibroblasts.
Using bone marrow chimeras and transgenic reporter mice,
the authors estimate that resident fibroblasts, epithelial–me-
senchymal transformation, and circulating precursors con-
tribute 52, 38, and 9%, respectively.
More recently, Zeisberg et al.30 have demonstrated, using
lineage tracing techniques in mice, that endothelial–
mesenchymal transformation may also contribute to the
fibroblast populations observed in renal disease. They
demonstrated that 30–50% of fibroblasts seen in an animal
model of renal fibrosis coexpressed the endothelial cell
marker CD31 and both fibroblast and myofibroblast surface
markers.30 Here, we describe a novel subset of CD248þ
aSMAþ myofibroblasts and also a population of CD248þ
aSMA fibroblasts, thus emphasizing the heterogeneity of
the fibroblast and myofibroblast populations found in CKD.
aSMA fibroblasts are described in the renal literature and are
known to contain and express interstitial collagens in vivo.31
Further fibroblasts isolated from a-SMA-null mice produce
more type collagen 1 compared with wild-type controls.3
Elegant studies by Lin et al.32 have highlighted the impor-
tance of the renal pericyte and of injury to the vasculature in
driving fibrosis. Using a transgenic reporter mouse, they
demonstrated that activation of pericytes and peritubular
fibroblasts contributed significantly to interstitial myofibro-
blast populations in experimental renal fibrosis. Their
observations from murine models of renal injury are
supported further by our identification of CD248 expression
by resident renal pericytes in close approximation to the
vasculature and the accompanying upregulation of CD248 in
human disease. However, our studies fall short of demon-
strating categorically that in progressive human renal disease,
CD248þ cells, or a sub-population thereof, are derived from
pericytes.
The extent of tubulointerstitial fibrosis seen in kidney
biopsy has been repeatedly demonstrated to be a rigorous
predictor of renal progression,12,33 and our data are the latest
confirmation of this long-known association. This study does
not, however, demonstrate that a causal role is played by
CD248 in progressive renal scarring, but the close association
with albuminuria and renal scarring, which are known
determinants of renal disease progression, and also the
association between CD248 and renal survival outcomes is
intriguing. Importantly, this relationship is maintained in
our multivariate analysis.
In conclusion, we have demonstrated that the stromal
fibroblast and pericyte marker CD248 is upregulated in
chronic kidney disease and that this is linked to known
determinants of renal progression. The expression of CD248
on stromal fibroblasts and pericytes is already robustly
established in the literature. However, here we report the
additional observation that CD248 defines a sub-population
of myofibroblasts and also a sub-population of CD248þ
aSMA fibroblasts that are linked to albuminuria and
tubulointerstitial damage, suggesting that CD248 may be
implicated in the tissue remodeling seen in CKD. Immuno-
staining for CD248-positive cells may not only provide a
valuable histological guide to predict renal progression, but
also raise the possibility that CD248-positive stromal cells
may be a potential target for the modulation of renal disease
using novel antiangiogenic drugs such as the anti-human
CD248 monoclonal antibody MORAb-004.
MATERIALS AND METHODS
Anti-human CD248 antibody
The generation of the human anti-CD248 monoclonal antibody
(B1/35) has been described previously.13
Cell culture
Immortalized glomerular endothelial cells and podocytes were a
kind gift from Dr Simon Satchell (University of Bristol, Bristol, UK).
Following NRES (National Research Ethics Service) ethical approval
(Research Ethics Committee approval number 08/H1203/8) and
under the regulations described within the Human Tissue Act 2004,
human renal fibroblasts were isolated using the explant method of
Grimwood et al.34 from the normal pole of nephrectomy samples
removed for the treatment of malignant disease. Fibroblasts stained
negative for CD31, cytokeratin, and desmin, but positive for
vimentin. Passages 2–8 were used for all in vitro studies.
Immunocytochemistry
Cells were seeded onto glass chamber slides (Becton Dickinson
Falcon, San Diego, CA) at 10,000 cells per well and were allowed to
grow to confluence at 37 1C. They were then fixed with methanol at
20 1C and stained with either anti-human CD248 or mouse IgG1
(Dako, Cambridge, UK) overnight at 4 1C. Goat anti-mouse IgG1
conjugated to Alexa 488 (Invitrogen, Paisley, UK) was then applied
and the slides were visualized using a Zeiss confocal LSM 510
microscope (Zeiss, Gottingen, Germany) and processed using Zeiss
LSM Image Examiner software (Zeiss).
Reverse transcription-PCR
Cells were grown to confluence in six-well plates. A Qiagen RNeasy
Mini Kit (Qiagen, Valencia, CA) was used to isolate RNA according
to the manufacturer’s protocol. Complementary DNAwas generated
using TaqMan Reverse Transcription (Applied Biosystems, Carlsbad,
CA). PCR was performed using the following primers: CD248
forward 50-TTTGGCTTCGAGGGCGCCTG-30, CD248 reverse 50-
TCACACTGCTGCTCGCACGG-30; TBP forward 50-AACTTCGCTTC
CGCTGGCCC-30, TBP reverse 50-GCTGTGGTGCCTGGCCTGAG-30
(Alta Bioscience, Birmingham, UK).
Western blotting
Cells were lysed in CellLyticMT (Sigma, York, UK) sample buffer
and 22.5mg of protein per sample was run on a 10% sodium
dodecyl sulfate polyacrylamide gel electrophoresis gel. Gels were
transferred onto nitrocellulose membrane, blocked with 5% milk,
and incubated with the primary antibodies: B1/35 and b-actin
(Sigma), followed by horseradish peroxidase-conjugated anti-mouse
IgG (Amersham, Buckinghamshire, UK). Immunodetection was
carried out using the ECL Kit (Amersham) followed by exposure to
X-ray film for 15min.
Kidney International (2011) 80, 199–207 205
SW Smith et al.: CD248þ stromal cells and progressive CKD o r ig ina l a r t i c l e
Mice
Wild-type 129SvEv mice were obtained from Harlan UK (Oxford,
UK). All experiments were performed in accordance with UK laws
and with the approval of the local ethics committees. Kidney tissue
samples were removed from adult mice (n¼ 6) and snap frozen in
liquid nitrogen. Frozen 6 mm sections were cut for staining.
Patient samples
Following local ethical approval (NRES 07/Q2602/42), we identi-
fied patients who underwent a percutaneous renal biopsy at the
University Hospital Birmingham NHS Foundation Trust for the
investigation of renal disease between June 1998 and November
2009. A randomly selected prevalent cohort of 100 patients with a
histological diagnosis of IgA nephropathy, who also had archived
formal-saline fixed paraffin tissue, was used for the study. Clinical
and demographic data were collected from patient records. Normal
tissue sections were taken from nephrectomy samples and also
purchased commercially (Abcam, Cambridge, UK).
Immunohistochemistry for CD248
The immunohistochemical detection of CD248 was performed
using established methods. Briefly, 4 mm tissue sections were cut
onto glass slides from paraffin blocks. Sections were dewaxed in
xylene and rehydrated through a series of graded alcohols to water.
Antigen retrieval was performed using Dako Target Antigen
Retrieval solution in a water bath at 95 1C for 30min. Sections
were stained according to the Dako mouse Envision-HRP kit
protocol with monoclonal mouse anti-human CD248 (Clone B1/35,
in-house antibody) at a concentration of 0.2 mg/ml overnight at
4 1C. Sections were then either counterstained with Mayer’s
hematoxylin for CD248 localization or left unstained for quantita-
tive analysis. Mouse IgG1 (Dako) was used as an isotype control and
substituted for primary antibody on serial sections.
Quantification of interstitial CD248 expression
An interactive image analysis system was used for blinded
assessment of interstitial CD248 fibroblast numbers. We have
previously found this to be a reliable method in the analysis of
renal tissue sections.12,24
The sections were blinded to the operator and stained for
CD248. They were visualized at  200 magnification and images
were captured using a Nikon Eclipse E400 microscope with a digital
imaging system controlled by NIS Elements Version 3.0 (Nikon,
Kingston Upon Thames, UK). Images were stored as TIFF files and
imported into Aequitas IA image analysis software (DynamicData
Links, Cambridge, UK) where the digitalized image is converted to a
two-color scale image. Using the threshold function, the image was
processed so that positive staining was represented by yellow pixels
measured as a percentage of the area of total image analyzed.
Sections with excessive background staining that made it impossible
to digitally differentiate specific staining were excluded from
analysis. For each patient, the mean measurement of interstitial
CD248 staining of five randomly selected nonconfluent microscopic
fields was determined. Blood vessel and glomerular staining was
identified by the operator and excluded from the analysis using the
computer software.
Quantification of chronic damage
The extent of chronic tissue damage within each biopsy specimen
was assessed using the index of chronic damage, an established
and rigorous predictor of renal outcome previously developed by
our group.35 For each biopsy, one section was stained by periodic
acid-methenamine silver and assessed morphometrically using
this method.
Confocal microscopy
Confocal microscopy was performed on 4 mm tissue sections cut
from paraffin blocks using the methods of Robertson et al.36 The
following antibodies were used: monoclonal mouse IgG1 anti-
human CD248 and monoclonal mouse IgG2 anti-human a-SMA
(R&D Research Systems, Oxford, UK). Goat anti-mouse IgG1
conjugated to Alexa 488 or goat anti-mouse IgG2a conjugated to
Alexa 633 (Invitrogen) was then applied and the slides were
visualized using a Zeiss confocal LSM 510 microscope (Zeiss) and
processed using Zeiss LSM Image Examiner software (Zeiss).
Frozen murine tissue was stained with: polyclonal rabbit anti-
mouse CD248 (in-house), hamster anti-mouse CD31, rat anti-
mouse platelet-derived growth factor receptor-b, rat anti-mouse
synaptopodin, and rat anti-mouse E-cadherin (eBioscience, San
Diego, CA). For staining of platelet-derived growth factor receptor-
b, 0.5% Tween was added to the antibody buffer.
Statistics
Linear regression analyses were performed to determine correlations
between normally distributed data variables. Variables determined to
not follow a Gaussian distribution by normality testing for skewness
were normalized by transformation before analysis. Correlations are
presented by expressing the b-correlation coefficient along with the
P-value. Linear regression multivariate analysis of these correlations
with a dependent variable was also performed. Renal outcome was
assessed by Kaplan–Meier survival analysis with log rank testing after
categorization of tubulointerstitial CD248 expression into tertiles.
End points were either doubling of serum creatinine concentration
or end-stage renal failure, defined by requirement of dialysis. All
statistical tests were performed using SPSS (IBM, Middlesex, UK).
Graphs were created using Prism 4 (GraphPad, San Diego, CA). The
level of significance was set at Po0.05.
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